Skip to content

US · EXOZ · BIOTECHNOLOGY

eXoZymes, Inc. (EXOZ) intrinsic value and stock valuation

$2.91as of 2026-11-21 · Mkt cap 50.49M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

eXoZymes, Inc. DCF and intrinsic value

InvestorsCraft values EXOZ with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from EXOZ’s statements →

eXoZymes, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Monrovia, CA 91016 exozymes.com

How the business is doing

Fiscal 2021–2025, USD

Revenue
$0.00
20212025
Net income
-$-9.16M
20212025
Free cash flow
-$-6.67M
20212025
Total equity
$3.4M
20212025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2021–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-9.72M-$-5.93M-$-1.8M-$-1.33M-$-1.29M
Net income-$-9.16M-$-5.86M-$-2.04M-$-1.4M-$-1.21M
EPSd-$-1.09M-$-720.79K-$-250.92K-$-172.2K-$-148.83K
Operating cash flow-$-6.5M-$-8.51M-$-1.18M-$-1.26M-$-1.59M
Capital expenditure-$-170K-$-400K-$-290K-$-190K-$-420K
Free cash flow-$-6.67M-$-8.9M-$-1.47M-$-1.44M-$-2.01M
Total assets$5.97M$13M$3.56M$2.69M$2.35M
Total debt$1.24M$1.39M$1.61M$610K$720K
Net debt-$-1.8M-$-8.33M$1.55M$50K$170K
Total equity$3.4M$10.4M-$-380K$1.37M$1.2M
Cash and short-term investments$3.04M$9.72M$70K$560K$550K
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$270K$0.00$150K$60K
Gross profit$0.00-$-270K$0.00-$-150K-$-60K
Research and development expenses$3.71M$1.87M$530K$350K$450K
Selling, general and administrative expenses$5.91M$3.8M$1.34M$840K$780K
Other expenses$100K$0.00-$-70K$0.00$0.00
Operating expenses$9.72M$5.66M$1.8M$1.18M$1.23M
Cost and expenses$9.72M$5.93M$1.8M$1.33M$1.29M
Interest income$0.00$80K$0.00$0.00$0.00
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$290K$270K$200K$150K$60K
Ebitda-$-8.98M-$-5.59M-$-1.8M-$-1.18M-$-1.15M
Operating income-$-9.72M-$-5.93M-$-1.8M-$-1.33M-$-1.29M
Total other income/expenses, net$450K$70K-$-200K$0.00$80K
Income before tax-$-9.26M-$-5.86M-$-2M-$-1.33M-$-1.21M
Income tax expense-$-110K$0.00$40K$60K$0.00
Net income-$-9.16M-$-5.86M-$-2.04M-$-1.4M-$-1.21M
Weighted average shares outstanding$8.38M$8.13M$8.13M$8.13M$8.13M
Weighted average diluted shares outstanding$8.38M$8.13M$8.13M$8.13M$8.13M
Balance sheet
20252024202320222021
Cash and short-term investments$3.04M$9.72M$70K$560K$550K
Net receivables$520K$740K$880K$810K$470K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$3.94M$10.8M$1.21M$1.47M$1.05M
Property, plant and equipment, net$2.21M$2.21M$2.34M$1.22M$1.3M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$2.03M$2.21M$2.34M$1.22M$1.3M
Total assets$5.97M$13M$3.56M$2.69M$2.35M
Accounts payable$1.24M$920K$700K$390K$270K
Short-term debt$330K$230K$220K$150K$130K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.57M$1.33M$2.42M$630K$400K
Long-term debt$920K$1.16M$1.39M$460K$590K
Deferred revenue, non-current$0.00$0.00$140K$210K$160K
Total non-current liabilities$1.01M$1.28M$1.53M$680K$750K
Capital lease obligations$1.24M$1.39M$1.61M$610K$720K
Total liabilities$2.57M$2.61M$3.94M$1.31M$1.15M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-21.1M-$-11.95M-$-6.08M-$-4.05M-$-2.65M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$3.4M$10.4M-$-380K$1.37M$1.2M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$1.24M$1.39M$1.61M$610K$720K
Net debt-$-1.8M-$-8.33M$1.55M$50K$170K
Cash flow statement
20252024202320222021
Net income-$-9.16M-$-5.86M-$-2.04M-$-1.4M-$-1.21M
Depreciation and amortization-$-50K$270K$200K$150K$60K
Stock-based compensation$1.99M$1.13M$280K$220K$200K
Change in working capital$380K-$-4.02M$220K-$-190K-$-540K
Accounts receivable$110K$150K-$-70K-$-340K-$-320K
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$310K$220K$270K$120K-$-210K
Net cash provided by operating activities-$-6.5M-$-8.51M-$-1.18M-$-1.26M-$-1.59M
Investments in property, plant and equipment-$-170K-$-400K-$-290K-$-190K-$-420K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-150K-$-360K-$-310K-$-90K-$-310K
Common stock issued$0.00$14.5M$0.00$1.36M$2.31M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-30K$18.5M$1M$1.36M$2.31M
Net change in cash-$-6.68M$9.65M-$-490K$10K$410K
Cash at end of period$3.04M$9.72M$70K$560K$550K
Operating cash flow-$-6.5M-$-8.51M-$-1.18M-$-1.26M-$-1.59M
Capital expenditure-$-170K-$-400K-$-290K-$-190K-$-420K
Free cash flow-$-6.67M-$-8.9M-$-1.47M-$-1.44M-$-2.01M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About eXoZymes, Inc.

        eXoZymes, Inc. operates as a development stage biotechnology company. It focuses on the development of enzyme modules and cell-free exozyme biosolutions for synthetic biology manufacturing. The company was formerly known as Invizyne Technologies, Inc. and changed its name to eXoZymes, Inc. in February 2025. eXoZymes, Inc. was incorporated in 2014 and is headquartered in Monrovia, California.

        CEO
        Michael Heltzen
        Employees
        32
        Beta
        2.93

        Explore

        Frequently asked questions

        What is the intrinsic value of eXoZymes, Inc. (EXOZ)?

        InvestorsCraft does not currently publish an intrinsic value for EXOZ. How the IC value is calculated.

        Is EXOZ undervalued?

        InvestorsCraft does not publish an undervaluation signal for EXOZ at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.